Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era

Roger A Barker; Malin Parmar; Lorenz Studer; Jun Takahashi

doi:10.1016/j.stem.2017.09.014

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era

Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

Authors

Roger A Barker¹, Malin Parmar², Lorenz Studer³, Jun Takahashi⁴

Affiliations

¹ Department of Clinical Neuroscience and Cambridge Stem Cell Institute, Forvie Site, Cambridge CB2 0PY, UK.
² Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, and Lund Stem Cell Centre, Department of Experimental Medical Science, Lund University, 22184, Lund, Sweden. Electronic address: malin.parmar@med.lu.se.
³ Developmental Biology, The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA.
⁴ Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 606-8507, Kyoto, Japan.

PMID: 29100010
DOI: 10.1016/j.stem.2017.09.014

Abstract

Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.

MeSH terms

Adult
Aged
Clinical Trials as Topic*
Dopaminergic Neurons / transplantation*
Humans
Middle Aged
Parkinson Disease / therapy*
Stem Cell Transplantation*

Grants and funding

MC_PC_12009/MRC_/Medical Research Council/United Kingdom